Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials.

Kiem D, Ocker M, Greil R, Neureiter D, Melchardt T.

Expert Opin Investig Drugs. 2024 Feb 23:1-14. doi: 10.1080/13543784.2024.2319317. Online ahead of print. PMID: 38354028.